CAS 267243-28-7

Canertinib

Description:

Canertinib is a small molecule tyrosine kinase inhibitor primarily used in the treatment of certain types of cancer, particularly non-small cell lung cancer and breast cancer. It selectively targets the epidermal growth factor receptor (EGFR) and other members of the ErbB family, inhibiting their activity and thereby interfering with cancer cell proliferation and survival. The chemical formula of Canertinib reflects its complex structure, which includes multiple functional groups that contribute to its pharmacological properties. It is typically administered orally and has been studied for its potential to overcome resistance to other EGFR inhibitors. Canertinib's mechanism of action involves blocking the phosphorylation of tyrosine residues on the receptor, which is crucial for downstream signaling pathways that promote tumor growth. As with many targeted therapies, its use may be associated with specific side effects, and its efficacy can vary based on the genetic profile of the tumor. Ongoing research continues to explore its applications and combinations with other therapeutic agents in oncology.

Formula: C₂₄H₂₅ClFN₅O₃

InChI: InChI=1/C23H23ClFN5O3/c1-2-22(31)29-20-12-16-19(13-21(20)33-10-7-30-5-8-32-9-6-30)26-14-27-23(16)28-15-3-4-18(25)17(24)11-15/h2-4,11-14H,1,5-10H2,(H,29,31)(H,26,27,28)

InChI key: InChIKey=OMZCMEYTWSXEPZ-UHFFFAOYSA-N

SMILES: N(C=1C2=C(C=C(OCCCN3CCOCC3)C(NC(C=C)=O)=C2)N=CN1)C4=CC(Cl)=C(F)C=C4

Synonyms:

• 2-Propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-
• 4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propyloxy]-6-[(vinylcarbonyl)amino]quinazoline
• Canertinib base
• Cl 1033
• N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide
• N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide
• N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[2-(morpholin-4-yl)ethoxy]quinazolin-6-yl}prop-2-enamide
• N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide
• Canertinib
• N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide
• N-[4-(3-Chloro-4-fluoroanilino)-7-(3-morpholinopropoxy)quinazolin-6-yl]acrylamide Canertinib (CI-1033)
• N-(4-((3-Chloro-4-fluorophenyl)
• N-[4-(3-chloro-4-fluoro-anilino)-7-(3-morpholinopropoxy)quinazolin-6-yl]acrylamide
• N-(4-(3-chloro-4-fluorophenylamino)-7-(3-morpholinopropoxy)quinazolin-6-yl)acrylamide
• CI-1033(Canertinib)
• N-[4-(3-chloro-4-fluoroanilino)-7-(3-Morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-en
• PD-183805
• quinazolin-6-yl)
• Canertinib--CI-1033, PD-183805
• Canetinib
• Canertinib N-[4-(3-Chloro-4-fluoroanilino)-7-(3-morpholinopropoxy)quinazolin-6-yl]acrylamide
• -7-(3-morpholinopropoxy)

Canertinib

CAS: 267243-28-7

Formula: C₂₄H₂₅ClFN₅O₃

Purity: 98%

Color and Shape: Solid

Molecular weight: 485.9384

Ref: IN-DA00BCK6

Canertinib

CAS: 267243-28-7

Canertinib

Purity: ≥98%

Molecular weight: 485.94g/mol

Ref: 54-BUP06272

Canertinib

CAS: 267243-28-7

Formula: C₂₄H₂₅ClFN₅O₃

Purity: >98.0%(HPLC)(qNMR)

Color and Shape: White to Light yellow powder to crystal

Molecular weight: 485.94

Ref: 3B-C3818

Canertinib

CAS: 267243-28-7

Ref: 7W-GW7411

Canertinib

CAS: 267243-28-7

Canertinib (CI-1033), a pan-erbB inhibitor, effectively targets esophageal cancer in vitro/vivo, altering metabolism and reducing growth and hypoxia.

Formula: C₂₄H₂₅ClFN₅O₃

Purity: 98% - >99.99%

Color and Shape: White Or Similar To White Crystalline Powder

Molecular weight: 485.94

Ref: TM-T6136

Canertinib

CAS: 267243-28-7

Purity: 98%

Molecular weight: 485.940002441406

Ref: 10-F863395